Beta Bionics reported revenue of $32.01M and net income of -$23.70M for the quarter ended Jun 2026, up 37.8% year over year. This income statement covers 11 quarters of results from Dec 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||
| Revenue | 12.93M | 15.05M | 16.70M | 20.44M | 17.64M | 23.24M | 27.25M | 32.12M | 27.63M | 32.01M | |
| Cost of RevenueCost of Rev | 5.73M | 6.96M | 7.79M | 8.75M | 8.67M | 10.73M | 12.13M | 13.18M | 11.19M | 13.11M | |
| Gross Profit | 7.20M | 8.08M | 8.91M | 11.69M | 8.97M | 12.50M | 15.12M | 18.94M | 16.44M | 18.90M | |
| Operating items | |||||||||||
| Research & DevelopmentR&D | 7.66M | 8.97M | 9.64M | 10.80M | 13.40M | 15.62M | 16.05M | 16.33M | 20.73M | 24.64M | |
| Selling, General & AdministrativeSG&A | 3.51M | 4.54M | 5.11M | 4.71M | 6.62M | 7.88M | 7.92M | 8.60M | 9.62M | 9.60M | |
| Other Operating ExpensesOther Opex | 5.48M | 6.35M | 5.14M | 9.21M | 7.59M | 8.87M | 8.20M | 10.13M | 10.36M | 10.24M | |
| Operating ExpensesOpex | 16.65M | 19.87M | 19.89M | 24.73M | 27.61M | 32.38M | 32.16M | 35.07M | 40.71M | 44.48M | |
| Operating IncomeOp. Inc | -9.45M | -11.78M | -10.98M | -13.04M | -18.64M | -19.87M | -17.04M | -16.12M | -24.27M | -25.58M | |
| EBIT | -9.45M | -11.78M | -10.98M | -13.04M | -18.64M | -19.87M | -17.04M | -16.12M | -24.27M | -25.58M | |
| Non-operating items | |||||||||||
| Interest & Investment IncomeInt & Inv Inc | 1.14M | 0.99M | 0.83M | 0.95M | 2.44M | 3.00M | 2.83M | 2.66M | 2.38M | 2.18M | |
| Other Non Operating IncomeOther Non Op Inc. | 0.00M | -0.00M | -0.00M | -0.00M | 0.00M | -0.00M | |||||
| Non Operating IncomeNon Op. Inc. | -3.00M | -2.68M | 1.24M | -5.07M | -10.01M | 3.00M | 2.83M | 2.66M | 2.38M | 2.17M | |
| Net income details | |||||||||||
| EBT | -8.31M | -10.79M | -10.15M | -12.09M | -16.21M | -16.87M | -14.21M | -13.47M | -21.89M | -23.40M | |
| Profit After TaxPAT | -12.58M | -14.49M | -9.74M | -18.10M | -28.66M | -16.96M | -14.21M | -13.47M | -22.39M | -23.70M | |
| Income from Continuing OperationsIncome (Continuing) | -8.31M | -10.79M | -10.15M | -12.09M | -16.21M | -16.87M | -14.21M | -13.47M | -21.89M | -23.40M | |
| Consolidated Net IncomeConsol Net Inc. | -8.31M | -10.79M | -10.15M | -12.09M | -16.21M | -16.87M | -14.21M | -13.47M | -21.89M | -23.40M | |
| Income towards Parent CompanyParent Net Inc | -8.31M | -10.79M | -10.15M | -12.09M | -16.21M | -16.87M | -14.21M | -13.47M | -21.89M | -23.40M | |
| Net Income towards Common StockholdersNet Income | -8.31M | -10.79M | -10.15M | -12.09M | -16.21M | -16.87M | -14.21M | -13.47M | -21.89M | -23.40M | |
| Additional items | |||||||||||
| EPS (Basic) | -1.38 | -1.77 | -1.52 | -1.90 | -0.53 | -0.39 | -0.33 | -0.33 | -0.49 | -0.53 | |
| EPS (Diluted) | -1.38 | -1.77 | -1.52 | -1.90 | -0.53 | -0.39 | -0.33 | -0.33 | -0.49 | -0.53 | |
| Shares Outstanding | 5.30M | 6.02M | 6.11M | 6.66M | 6.37M | 30.71M | 43.39M | 43.63M | 40.53M | 44.44M | 44.55M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 5.30M | 6.02M | 6.11M | 6.66M | 6.37M | 30.71M | 43.39M | 43.63M | 40.53M | 44.44M | 44.55M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 6.02M | 6.02M | 6.66M | 6.66M | 6.67M | 30.71M | 43.47M | 43.99M | 44.36M | 44.56M | 44.98M |
| EBITDA | -9.45M | -11.78M | -10.98M | -13.04M | -18.64M | -19.87M | -17.04M | -16.12M | -24.27M | -25.58M |